What is Novo Nordisk's expected EPS for Q2 2026?

Analysts expect Novo Nordisk (NVO) to report consensus EPS of approximately DKK4.98 for Q2 2026. Estimates range from DKK4.96 to DKK5.02.

What revenue do analysts expect for Novo Nordisk in Q2 2026?

The consensus revenue forecast for Novo Nordisk (NVO) in Q2 2026 is approximately 71.4B DKK. Forecasts range from 69.6B DKK to 72.9B DKK.

How many analysts cover Novo Nordisk?

3 analysts contribute to the Novo Nordisk (NVO) Q2 2026 consensus estimate.

Has Novo Nordisk beaten earnings estimates recently?

Novo Nordisk beat analyst EPS estimates in 0 of the last 2 quarters. Novo Nordisk beat revenue estimates in 0 of 2. In the most recent quarter (Q1 2026), Novo Nordisk EPS missed by 81.9% and revenue missed by 84.4%.

When does Novo Nordisk report Q2 2026 earnings?

Novo Nordisk (NVO) is expected to report Q2 2026 earnings on August 5, 2026 before market open.

NVO Q2 2026 earnings estimate

Consensus EPS · Q2 2026

DKK 4.98

Consensus revenue · Q2 2026

71.4B DKK

Analysts

Expected report

Aug 5, 2026

Before open

Upcoming earnings

Locks in 12 days 11 hours · BMO: Locks 8:00 PM ET previous day

Revenue71.4B DKK69.6B DKK – 72.9B DKK

EPSDKK 4.98DKK 4.96 – DKK 5.02

What to watch

Analyst ratings: Mixed

Make your prediction

Analyst consensus

Based on estimates from 3 analysts.

Metric	Low	Consensus	High
Revenue	69.6B DKK	71.4B DKK	72.9B DKK
EPS	DKK 4.96	DKK 4.98	DKK 5.02
EBITDA	39.6B DKK	41.2B DKK	42.8B DKK
EBIT	32.5B DKK	33.8B DKK	35.1B DKK
Net income	21.3B DKK	22.7B DKK	24.1B DKK

Revenue71.4B DKK
EPSDKK 4.98
EBITDA41.2B DKK
EBIT33.8B DKK
Net income22.7B DKK

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	11B DKK	70.5B DKK	-84.4%	DKK 1.04	DKK 5.74	-81.9%
Q4 2025	12.5B DKK	77.1B DKK	-83.8%	DKK 1.02	DKK 5.87	-82.6%

Q1 2026-84.4%-81.9%
Q4 2025-83.8%-82.6%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Grade F — Strong downward revisions

Metric	Now	30d ago	60d ago	90d ago	30d Δ
Revenue	71.8B DKK	72.8B DKK	—	—	-1.3%
EPS	DKK 5.15	DKK 5.34	—	—	-3.5%

0 revised up (30d)2 revised down (30d)

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for Novo Nordisk (NVO) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 0 analysts.

Low: $45.00
Consensus: $45.00
Median: $45.00
High: $45.00
Current: $48.19
Upside: -6.6%

Upside calculated vs most recent trading price of $48.19.

Analyst ratings

Consensus: Buy — based on 39 analyst ratings.

Strong Buy 1Buy 22Hold 13Sell 3

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Mar 2, 2026	Goldman Sachs	downgrade	Buy	Neutral
Feb 24, 2026	JP Morgan	downgrade	Overweight	Neutral
Dec 8, 2025	Argus Research	downgrade	Buy	Hold
Nov 28, 2025	Goldman Sachs	maintain	Buy	Buy
Nov 25, 2025	BMO Capital	maintain	Market Perform	Market Perform
Nov 24, 2025	HSBC	downgrade	Buy	Hold
Oct 14, 2025	BMO Capital	maintain	Market Perform	Market Perform
Oct 2, 2025	HSBC	upgrade	Hold	Buy
Sep 29, 2025	Morgan Stanley	downgrade	Equal Weight	Underweight
Sep 17, 2025	Berenberg	upgrade	Hold	Buy

Mar 2, 2026Goldman SachsNeutral
Feb 24, 2026JP MorganNeutral
Dec 8, 2025Argus ResearchHold
Nov 28, 2025Goldman SachsBuy
Nov 25, 2025BMO CapitalMarket Perform
Nov 24, 2025HSBCHold
Oct 14, 2025BMO CapitalMarket Perform
Oct 2, 2025HSBCBuy
Sep 29, 2025Morgan StanleyUnderweight
Sep 17, 2025BerenbergBuy

Frequently asked questions

Novo Nordisk (NVO) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

NVO Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation